Form 4: Intellia Therapeutics Officer Sells Shares for Tax

Intellia Therapeutics EVP Eliana Clark sold 9,515 shares of common stock to cover tax obligations upon RSU vesting, not a volitional trade.

Summary

• Eliana Clark, EVP, Chief Technical Officer of Intellia Therapeutics, Inc. (NTLA), reported a transaction involving the company's common stock.
• On January 5, 2026, Clark disposed of 9,515 shares of common stock at a price of $9.21 per share.
• This transaction was a mandatory "sell-to-cover" to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) on January 1, 2026, and was not a volitional trade.
• Following this transaction, Clark beneficially owns 87,118 shares of common stock directly.
• The reported beneficial ownership includes 1,264 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2025.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-volitional 'sell-to-cover' for tax purposes, which is neutral in terms of sentiment regarding the company's prospects. It does not indicate positive or negative sentiment from the insider.

Positives

• The acquisition of 1,264 shares under the Employee Stock Purchase Plan on December 31, 2025, indicates continued participation in employee benefit programs.

Negatives

• No specific negatives are indicated by this routine, non-volitional transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The transaction represents a mandatory "sell-to-cover" for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026.
• The transaction does not represent a volitional trade by the Reporting Person.

Industry Context

This routine insider transaction, a mandatory 'sell-to-cover' for tax purposes, is common practice across industries for executives receiving equity compensation. It does not reflect specific industry trends or competitive positioning for Intellia Therapeutics.

Comparison to Industry Standards

• This type of 'sell-to-cover' transaction is a standard mechanism for executives in publicly traded companies, particularly in the biotechnology sector, to manage tax liabilities arising from the vesting of equity awards. It is a common and expected event and does not provide a basis for comparison to specific company performance or projects.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-volitional transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact beyond the reporting person's compensation structure.

Key Dates

Recommendation

The reported transaction is a mandatory 'sell-to-cover' to satisfy tax obligations upon RSU vesting, explicitly stated as non-volitional. This type of transaction is a routine administrative event and does not reflect the insider's discretionary view on the company's future prospects or stock valuation. Therefore, it provides no new fundamental information to warrant a change in investment recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Transaction, Stock Sale, Executive Compensation, RSU Vesting, Tax Withholding, Eliana Clark, Biotechnology